• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·003000.KS
Share

Bukwang Pharmaceutical Co., Ltd. Stocks

₩ 3895Last Updated 16.11.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

₩ 294.88M

₩ 3895
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bukwang Pharmaceutical Co., Ltd., a South Korean-based enterprise, conducts pharmaceutical operations both domestically and across international markets. The company manufactures a diverse array of pharmaceutical formats, encompassing oral solids, injectables, liquid solutions, and topical preparations like external-use solutions and ointments. Its product portfolio spans key therapeutic domains such as hepatology, featuring treatments like Levovir and Legalon for liver conditions; products addressing diabetic complications, including Dexid and Thioctacid; central nervous system disorder medications like Lonasen, Ixel, and Orfil; and respiratory disease remedies such as Azeptin and Asima. In addition to its prescription drug offerings, Bukwang provides over-the-counter (OTC) products, personal care items like toothpastes, hair, and skin care goods, and various nutritional supplements. Its comprehensive lineup extends to numerous other therapeutic categories, covering antihistamines, gastrointestinal disorders, oncology, endocrine conditions (thyroid, diabetes, osteoporosis), obstetrics, urogenital health, cardiovascular care, dermatology, weight management, and pain relief. It also addresses a wide spectrum of common ailments, including respiratory symptoms (colds, coughs, asthma), inflammatory and pain conditions (rheumatoid arthritis, osteoarthritis, general pain), various skin issues (infections, irritations), digestive complaints, and nutritional needs, along with specialized remedies for conditions like varicose veins and lactation support. Furthermore, the company supplies quasi-drugs, medical devices, and health functional foods. Committed to innovation, Bukwang is deeply involved in developing new treatments. This includes an anti-diabetes compound in collaboration with Melior Pharmaceuticals, anti-cancer drugs with LSK BioPartners, and explorations into adult stem cell-based therapies. It also possesses a licensing agreement for a promising candidate drug targeting movement disorders in Parkinson's disease patients. Established in Seoul, South Korea, in 1960, Bukwang Pharmaceutical remains strategically headquartered there.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.11.2026 04:45

Bets Against AI and a “COVID-Related” Investment: Burry Reports on Deals Amid a Sell-Off

17.11.2026 04:30

"Everything Will Be Okay": OpenAI CEO Altman Dismisses the AI Industry's Concerns About Huang

17.11.2026 03:31

SpaceX stock retreats despite Starship test success. What is Wall Street saying?

17.11.2026 02:46

"The Music Fades": Bloomberg Names Neoclouds Vulnerable to a Change in Nvidia's Leadership

17.11.2026 02:19

The Nasdaq 100 IT Stock Index fell 2.7% at the start of a key week for the sector

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026